1. Phosphodiesterase type 10A inhibitor attenuates lung fibrosis by targeting myofibroblast activation
- Author
-
Ya-Jun Li, Jian-Rong Shi, Shu-Chan Li, Lu-Ming Wang, Rana Dhar, Ning Li, Xin-Wei Cao, Zi-Gang Li, and Hui-Fang Tang
- Subjects
Pharmacology ,Molecular biology ,Science - Abstract
Summary: Pulmonary fibrosis (PF) is a fatal and irreversible respiratory disease accompanied by excessive fibroblast activation. Previous studies have suggested that cAMP signaling pathway and cGMP-PKG signaling pathway are continuously down-regulated in lung fibrosis, whereas PDE10A has a specifically expression in fibroblasts/myofibroblasts in lung fibrosis. In this study, we demonstrated that overexpression of PDE10A induces myofibroblast differentiation, and papaverine, as a PDE10A inhibitor used for vasodilation, inhibits myofibroblast differentiation in human fibroblasts, Meanwhile, papaverine alleviated bleomycin-induced pulmonary fibrosis and amiodarone-induced oxidative stress, papaverine downregulated VASP/β-catenin pathway to reduce the myofibroblast differentiation. Our results first demonstrated that papaverine inhibits TGFβ1-induced myofibroblast differentiation and lung fibrosis by VASP/β-catenin pathway.
- Published
- 2023
- Full Text
- View/download PDF